Table 1.

Associations of urine T2:ERG score, urine PCA3 score, and the Mi-Prostate Score risk model for predicting cancer on biopsy and clinicopathologic parameters in evaluable validation cohort patients (n = 1225)

Parameter	Patients, n	Median, IQR	T2:ERG score, r_s	p value	PCA3 score, r_s	p value	MiPS model risk, r_s	p value
Age, yr	1225	64 (58-70)	0.10	0.0004	0.32	< 0.0001	0.32	<0.0001
Serum PSA	1225	4.7 (3.3-6.5)	0.07	0.01	0.11	< 0.0001	0.33	<0.0001
Ultrasound volume, ml	1181	48 (35-68)	−0.02	0.55	−0.08	0.006	0.00	0.90
PSAD	1181	0.091 (0.057-0.140)	0.08	0.008	0.17	< 0.0001	0.32	<0.0001
PCPTrc risk, %	1166	40 (33-51)	0.09	0.002	0.16	< 0.0001	0.32	<0.0001
PCPTrc high-grade risk, %	1218	11 (6-18)	0.09	0.001	0.25	< 0.0001	0.40	<0.0001
Bx cores, positive, no.	518	3 (1-5)	0.24	<0.0001	0.24	< 0.0001	0.34	<0.0001
Bx cores, positive, %	518	25 (8-42)	0.23	<0.0001	0.23	< 0.0001	0.34	<0.0001
Greatest involvement of a single bx core, %	201	38 (17-64)	0.27	0.0001	0.03	0.67	0.25	0.0003

Parameter	Total patients, n	Patients, n (%)	T2:ERG score, median (IQR)	p value	PCA3 score, median (IQR)	p value	MiPS model risk, median (IQR)	p value
Diagnosis	1225
Noncancer		707 (58)	2 (0-14)	<0.0001	15 (8-36)	<0.0001	30 (17-50)	<0.0001
Cancer		518 (42)	15 (1-71)		40 (19-84)		60 (38-76)
Diagnosis	707
Atypia and/or HGPIN		269 (38)	6 (0.5-25)	<0.0001	26 (12-57)	<0.0001	43 (26-63)	<0.0001
Other benign		438 (62)	1 (0-7)		12 (6-26)		24 (14-39)
Race	1222
White		890 (73)	5 (0.1-35)	0.07	26 (11-58)	0.002	42 (23-67)	0.01
Not white		332 (27)	4 (0-25)		21 (8-50)		38 (19-62)
Family History	1170
Negative		940 (80)	4 (0.1-33)	0.44	23 (10-55)	0.23	39 (21-65)	0.10
Positive		230 (20)	6 (0.3-28)		28 (11-61)		46 (24-67)
DRE	1223
Normal		936 (77)	5 (0.2-31)	0.40	24 (10-54)	0.22	42 (23-66)	0.17
Abnormal		287 (23)	5 (0-35)		27 (10-58)		37 (20-65)
Previous biopsy	1223
No		977 (80)	5 (0.1-33)	0.25	24 (10-57)	0.51	40 (21-66)	0.21
Yes		246 (20)	4 (0-31)		24 (12-53)		43 (25-65)
Bx cores (#)	773
<12		11 (1)	6 (0.5-70)	0.96	39 (17-68)	0.98	62 (50-79)	0.28
12		687 (89)	7 (0.3-48)		32 (15-73)		50 (30-71)
>12		75 (10)	6 (0.2-94)		32 (16-76)		44 (32-75)
Bx Gleason score	518
6		294 (57)	11 (0.7-52)	0.008	34 (16-75)	0.0006	53 (32-72)	<0.0001
>6		224 (43)	23 (2-113)		50 (23-94)		67 (46-81)
Clinical stage	517
T1		382 (74)	16 (1-68)	0.81	37 (19-78)	0.17	59 (39-76)	0.92
>T1		135 (26)	12 (0.4-95)		47 (20-95)		59 (35-77)
Bx signficance¹	195
Insignificant		32 (16)	5 (0.3-29)	0.24	34 (15-55)	0.008	44 (28-66)	0.007
Significant		163 (84)	15 (0.4-70)		50 (23-96)		63 (42-78)
Bx significance (pathology)²	201
Insignificant		65 (32)	5 (0.3-29)	0.004	36 (16-71)	0.002	45 (28-64)	<0.0001
Significant		136 (68)	22 (1-97)		55 (28-103)		68 (45-82)

Bx = biopsy; bx = previous biopsy; DRE = digital rectal examination; HGPIN = high-grade prostatic intraepithelial neoplasia; IQR = interquartile range; MiPS = Mi-Prostate Score, serum PSA plus T2:ERG plus PCA3; PCPTrc = Prostate Cancer Prevention Trial risk calculator; PSA = prostate-specific antigen; T2:ERG, TMPRSS2:ERG.

For all evaluable patients in the validation cohort, the number of patients with data for each parameter, the median (and interquartile range), and correlations (Spearman's rho [r_s]) and p values with urine T2:ERG score, urine PCA3 score, and the urine T2:ERG score plus urine PCA3 score plus serum PSA (MiPS) logistic regression model (logit) for predicting the presence of prostate cancer on biopsy are given in the upper panel. In the lower panel, the total number of patients with data for each parameter, the number (and percentage) of patients within each categorical parameter, and the median T2:ERG score, PCA3 score, and MiPS model (logit*100) and p value for each categorical comparison (Mann-Whitney or Kruskal-Walis test) are given.

Any clinical stage higher than T1c, PSA density (serum PSA/prostate volume on ultrasound) ≥0.15 ng/ml/ml, Gleason score >6, ≥25% cores positive, or >50% greatest single core Involvement as significant.

Any Gleason score >6, ≥25% cores positive, or >50% greatest single core involvement as significant.